New drug combo aims to tackle Hard-to-Treat prostate cancer

NCT ID NCT07336446

Recruiting now Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called AZD9750, alone or with another drug (saruparib), in 300 men with metastatic prostate cancer that has progressed despite standard treatments. The goal is to check safety, find the right dose, and see if it can lower PSA levels, a marker of cancer activity. It is an early-stage trial, so the main focus is on safety and tolerability.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AZD9750 (a drug that targets and breaks down the androgen receptor) and saruparib (a PARP1 inhibitor)
What this could lead to: If successful, this could lead to a new treatment option for men with metastatic prostate cancer that has stopped responding to standard hormone therapy.
What could go wrong: This is an early-phase trial (first-in-human) with only 300 participants, so the drug may not prove effective or may have unexpected side effects. Results may not apply to all prostate cancer patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Kennedy disease metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Research Site
RECRUITING

Duarte, California, 91010, United States
Research Site
NOT_YET_RECRUITING

San Francisco, California, 94143, United States
Research Site
NOT_YET_RECRUITING

Tampa, Florida, 33612, United States
Research Site
NOT_YET_RECRUITING

Boston, Massachusetts, 02114, United States
Research Site
RECRUITING

St Louis, Missouri, 63108, United States
Research Site
RECRUITING

Myrtle Beach, South Carolina, 29572, United States
Research Site
RECRUITING

Nashville, Tennessee, 37203, United States
Research Site
NOT_YET_RECRUITING

Salt Lake City, Utah, 84112, United States
Research Site
RECRUITING

Melbourne, 3000, Australia
Research Site
RECRUITING

Calgary, Alberta, T2N 5G2, Canada
Research Site
NOT_YET_RECRUITING

Vancouver, British Columbia, V5Z 1H7, Canada
Research Site
NOT_YET_RECRUITING

Chengdu, 610041, China
Research Site
NOT_YET_RECRUITING

Chūōku, 104-0045, Japan
Research Site
RECRUITING

Kashiwa, 227-8577, Japan
Research Site
NOT_YET_RECRUITING

Amsterdam, 1066CX, Netherlands
Research Site
NOT_YET_RECRUITING

Rotterdam, 3015 GD, Netherlands
Research Site
RECRUITING

Barcelona, 8035, Spain
Research Site
RECRUITING

Cambridge, CB2 2QQ, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.